Eli Lilly and Co., Lilly Corporate Center, Indianapolis, 46285 (www.lilly.com) discovers, develops, manufactures and sells pharmaceutical products for humans and animals. For the quarter ended Dec. 31, 2009, the company reported net income of $915.4 million, or 83 cents per diluted share, on $5.9 billion in revenue. That compares with a net loss of $3.6 billion, or $3.31 per diluted share, on $5.2 billion in revenue in the same period a year ago. The company’s shares trade on the New York Stock Exchange under the ticker symbol LLY. Information for Proxy Corner was taken from Bloomberg News and from the company’s proxy statement dated March 8, 2010.